Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

172.76USD
11 Dec 2017
Change (% chg)

$4.96 (+2.96%)
Prev Close
$167.80
Open
$168.75
Day's High
$173.78
Day's Low
$167.16
Volume
600,584
Avg. Vol
629,113
52-wk High
$256.78
52-wk Low
$160.09

Select another date:

Thu, Dec 7 2017

Fitch Affirms Allergan's 'BBB-' Rating; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, December 07 (Fitch) Fitch Ratings has affirmed the ratings of Allergan plc (Allergan; NYSE: AGN) and subsidiaries at 'BBB-'. The Rating Outlook is Stable. Fitch has also affirmed and withdrawn the 'BBB-' IDRs of Allergan's subsidiaries, Warner Chilcott Limited and Allergan Finance LLC. These IDRs are no longer considered by Fitch to be relevant to the agency's coverage. A full list of rating actions, which apply to approximatel

Tech firms tell patent court to ignore Allergan deal with tribe

Over 30 technology companies including Alphabet Inc , Amazon.com Inc and Facebook Inc. on Friday urged a U.S. patent court to disregard drugmaker Allergan Plc's contention that its transfer of some of its patents to a Native American tribe shields them from the court's review.

Tech firms tell patent court to ignore Allergan deal with tribe

Dec 1 Over 30 technology companies including Alphabet Inc, Amazon.com Inc and Facebook Inc. on Friday urged a U.S. patent court to disregard drugmaker Allergan Plc's contention that its transfer of some of its patents to a Native American tribe shields them from the court's review.

BRIEF-‍GIC Private reports a 5.11 pct passive stake in Allergan ​

* As of Nov 8, ‍GIC Private reports a 5.11 pct passive stake in - SEC filing ​ Source text: (http://bit.ly/2zMOtvp) Further company coverage:

BRIEF-Paulson & Co dissolves share stake in Facebook, cuts share stake in Allergan

* Paulson & Co Inc dissolves share stake in Facebook Inc ‍​- SEC filing

BRIEF-Omega Advisors takes share stake in Aetna, dissolves stake in Allergan

* Cuts share stake in AIG to 841,740 shares from 1.3 million shares

Allergan to sell a quarter of its Teva stake in first quarter 2018

NEW YORK Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.

Allergan to sell a quarter of its Teva stake in first quarter of 2018

NEW YORK Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.

Allergan to sell a quarter of its Teva stake in Q1 2018

NEW YORK, Nov 13 Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.

BRIEF-Allergan receives FDA approval for use of Vraylar in maintenance treatment of schizophrenia

* Allergan receives FDA approval for use of Vraylar (cariprazine) in the maintenance treatment of schizophrenia

Select another date: